| Read Time: < 1 minute | Defective Consumer Devices

Glyphosate Exposure Shown To Double Chance Of Cancer

2008 — Researchers concluded that glyphosate exposure doubled a person’s chances of developing non-Hodgkin’s lymphoma in 2008 following a study of Swedish citizens who were exposed to a number of pesticides. Reference:  Moncivais, Katy. “Roundup Cancer Lawsuit: 2020 Updates & Settlements.” Consumer Safety, 8 Jan. 2021, https://www.consumersafety.org/product-lawsuits/roundup/.

Continue Reading

| Read Time: < 1 minute | Defective Consumer Devices

Roundup’s Popularity Grows

2007 — Roundup became the most used herbicide in the U.S. by 2007.  The result of Roundup’s rising popularity was Roundup Ready crops, which began hitting the market in the late 1990s.  From the introduction of Roundup Ready crops through 2016, the global glyphosate usage increased by more than 15 times.  The U.S. made up 72% of the usage...

Continue Reading

| Read Time: < 1 minute | news

FDA Raises Concern about Incretin Mimetics

2007:  The Food and Drug Administration first raised concern about incretin mimetics in 2007.  They warned that incretin mimetics, especially exenatide (Byetta and Byuderon) and sitagliptin (Janumet and Januvia), could cause pancreatic diseases.  The warning followed reports that a rising number of incretin mimetics users were being diagnosed with acute pancreatitis and pancreatic cancer. Reference:  “FDA Investigating Reports of...

Continue Reading

| Read Time: < 1 minute | news

Study Found Taxotere Caused Permanent Alopecia in 6% of Women

December 2006 – A study conducted by the Rock Mountain Cancer Centers found that Taxotere caused 6% of women to suffer permanent alopecia. Reference: “Taxotere Lawsuit – Permanent Hair Loss and Illegal Marketing.” Drugwatch.com, 20 Apr. 2020, www.drugwatch.com/taxotere/lawsuits/

Continue Reading

| Read Time: < 1 minute | news

Taxotere Approved For Yet Another Cancer Treatment

October 2006 — Taxotere was approved for use in combination with cisplatin and fluorouracil for patients being treated for inoperable, locally advanced squamous cell carcinoma of the head and neck (SCCHN). Reference: “TAXOTERE® Receives U.S. FDA Approval for the Treatment of Patients with Head and Neck Cancer.” Sanofi, www.news.sanofi.us/press-releases?item=118381

Continue Reading

| Read Time: < 1 minute | news

Zostavax Approved by FDA

May 2006 — Zostavax was approved by the FDA for patients 60 and older. Reference: Reference:  Center for Biologics Evaluation and Research. “Zostavax.” U.S. Food and Drug Administration, FDA, www.fda.gov/vaccines-blood-biologics/vaccines/zostavax.

Continue Reading

| Read Time: < 1 minute | news

Taxotere Approved for Treatment of Advanced Gastric Adenocarcinoma

March 2006 — Taxotere was approved for use in combination with cisplatin and fluorouracil for patients being treated for advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy. Reference: “Taxotere Wins FDA Approval for Advanced Gastric Cancer.” Cancer Network, www.cancernetwork.com/view/taxotere-wins-fda-approval-advanced-gastric-cancer

Continue Reading

| Read Time: < 1 minute | news

Taxotere Approved to Treat Another Form of Breast Cancer

August 2004 — Taxotere was approved for use in combination with doxorubicin and cyclophosphamide for the adjuvant treatment of women with operable node-positive breast cancer. Reference: Martins, Ines. “Docetaxel (Taxotere).” Breast Cancer News, 19 Apr. 2016, breastcancer-news.com/docetaxel-taxotere/

Continue Reading

| Read Time: < 1 minute | news

Taxotere Approved for Use to Treat Type of Prostate Cancer

May 2004 – Taxotere was approved for use in combination with prednisone for the treatment of metastatic, androgen-independent prostate cancer. Reference: Martins, Ines. “Docetaxel.” Prostate Cancer News Today, 11 Mar. 2016, prostatecancernewstoday.com/docetaxel/

Continue Reading